Next Article in Journal
STAT3: Versatile Functions in Non-Small Cell Lung Cancer
Next Article in Special Issue
USP47 Promotes Tumorigenesis by Negative Regulation of p53 through Deubiquitinating Ribosomal Protein S2
Previous Article in Journal
TESC Promotes TGF-α/EGFR-FOXM1-Mediated Tumor Progression in Cholangiocarcinoma
Previous Article in Special Issue
S100A4 Is a Biomarker of Tumorigenesis, EMT, Invasion, and Colonization of Host Organs in Experimental Malignant Mesothelioma
Article

Molecular and Clinical Relevance of ZBTB38 Expression Levels in Prostate Cancer

1
Team Epigenetics, DNA replication and Cancer, Université de Paris, Institut Cochin, INSERM, F-75014 Paris, France
2
Neurobiology, Neurodegeneration & Repair Laboratory, National Eye Institute, National Institutes of Health, MSC0610, 6 Center Drive, Bethesda, MD 20892, USA
3
Team Genomics and Signalling of Endocrine Tumours, Université de Paris, Institut Cochin, INSERM, U1016, CNRS, UMR8104, F-75014 Paris, France
*
Authors to whom correspondence should be addressed.
Contributed equally to this work.
Cancers 2020, 12(5), 1106; https://doi.org/10.3390/cancers12051106
Received: 13 March 2020 / Revised: 12 April 2020 / Accepted: 23 April 2020 / Published: 29 April 2020
(This article belongs to the Collection Cancer Biomarkers)
Prostate cancer is one of the most commonly diagnosed cancers in men. A number of genomic and clinical studies have led to a better understanding of prostate cancer biology. Still, the care of patients as well as the prediction of disease aggressiveness, recurrence and outcome remain challenging. Here, we showed that expression of the gene ZBTB38 is associated with poor prognosis in localised prostate cancer and could help discriminate aggressive localised prostate tumours from those who can benefit only from observation. Analysis of different prostate cancer cohorts indicates that low expression levels of ZBTB38 associate with increased levels of chromosomal abnormalities and more aggressive pathological features, including higher rate of biochemical recurrence of the disease. Importantly, gene expression profiling of these tumours, complemented with cellular assays on prostate cancer cell lines, unveiled that tumours with low levels of ZBTB38 expression might be targeted by doxorubicin, a compound generating reactive oxygen species. Our study shows that ZBTB38 is involved in prostate cancer pathogenesis and may represent a useful marker to identify high risk and highly rearranged localised prostate cancer susceptible to doxorubicin. View Full-Text
Keywords: ZBTB38; prostate cancer; primary tumours; doxorubicin; genomic instability; SPOP; disease recurrence ZBTB38; prostate cancer; primary tumours; doxorubicin; genomic instability; SPOP; disease recurrence
Show Figures

Figure 1

MDPI and ACS Style

de Dieuleveult, M.; Marchal, C.; Jouinot, A.; Letessier, A.; Miotto, B. Molecular and Clinical Relevance of ZBTB38 Expression Levels in Prostate Cancer. Cancers 2020, 12, 1106. https://doi.org/10.3390/cancers12051106

AMA Style

de Dieuleveult M, Marchal C, Jouinot A, Letessier A, Miotto B. Molecular and Clinical Relevance of ZBTB38 Expression Levels in Prostate Cancer. Cancers. 2020; 12(5):1106. https://doi.org/10.3390/cancers12051106

Chicago/Turabian Style

de Dieuleveult, Maud, Claire Marchal, Anne Jouinot, Anne Letessier, and Benoit Miotto. 2020. "Molecular and Clinical Relevance of ZBTB38 Expression Levels in Prostate Cancer" Cancers 12, no. 5: 1106. https://doi.org/10.3390/cancers12051106

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop